Article

Differential effects of 5-aminolaevulinic acid photodynamic therapy and psoralen + ultraviolet A therapy on p53 phosphorylation in normal human skin in vivo.

University of Edinburgh, Divisin of Oncology, Cancer Research UK Cell Signalling Unit, South Crewe Road, Edinburgh EH4 2XU, UK.
British Journal of Dermatology (Impact Factor: 3.76). 12/2005; 153(5):1001-10. DOI: 10.1111/j.1365-2133.2005.06922.x
Source: PubMed

ABSTRACT Phosphorylation of the tumour suppressor p53 by the CK2/FACT pathway plays a central role in suppressing ultraviolet (UV)-induced skin cancer in animal models. Although p53 protein stabilization is induced after solar-simulated irradiation of human skin in vivo, p53 phosphorylation has not been defined.
To investigate the effects of clinically effective treatments for skin diseases including psoralen + UVA (PUVA) and photodynamic therapy (PDT) on p53 phosphorylation to determine whether the tumour-suppressing p53 kinase pathways are activated upon use of these therapies.
We used antibodies to the ATM/ATR and CK2/FACT phosphorylation sites on p53.
We found that p53 activation was induced selectively by PUVA treatment, while 8-oxo-7,8-dihydroguanine DNA damage was induced selectively by 5-aminolaevulinic acid (ALA)-PDT treatment. Importantly, PUVA treatment resulted in p53 kinase activation, as defined by p53 modification at AT (serine-15) and CK2/FACT (serine-392) sites within the proliferative compartment.
These data demonstrate that PUVA provokes accumulation and phosphorylation of p53 by AT and CK2/FACT within critical proliferative focal points (as determined by p63 colocalization studies) where DNA damage may lead to tumorigenesis. PDT is mechanistically distinct in that there is a lower level of induction of p53 expression with no evidence of AT- or CK2/FACT-mediated phosphorylation. This suggests that the type of DNA damage created by the reactive oxygen species generated by ALA-PDT does not induce the p53 pathway classically required for the repair of DNA photoadducts induced by UV.

0 Bookmarks
 · 
47 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The emergence of multidrug resistance (MDR), meaning that cancer cells develop simultaneous resistance to different drugs, has limited the clinical efficacy and application of chemotherapy. Pterostilbene, a naturally occurring phytoalexin exerts a variety of pharmacologic activities, including antioxidation, cancer prevention and cytotoxicity to various cancer cells. In this study, results approved the capability of pterostilbene to effectively inhibit the cell growth of docetaxel-induced multidrug resistance human lung cancer cells lines and such inhibition is through an induction of cell cycle arrest and apoptosis. Meanwhile, the observation of the formation of acidic vesicular organelles and LC3-II production revealed an induction of autophagy at an early stage by pterostilbene, which was triggered by an inhibition of the AKT and JNK and an activation of the ERK1/2 pathway. Furthermore, an inhibition of autophagy by pretreatment with 3-methyladenine, bafilomycin A1 or Beclin 1 siRNA was able to enhance pterostilbene-triggered apoptosis. In conclusion, this study demonstrate that pterostilbene causes autophagy and apoptosis in lung cancer cells. Furthermore, a combination of pterostilbene with autophagy inhibitors may strengthen the efficiency of proapoptotic chemotherapeutic strategies in both chemosensitive and chemoresistant lung cancer cells, which may be of great value for the clinical management of lung cancer patients with multidrug resistance.
    Toxicological Sciences 10/2013; · 4.33 Impact Factor
  • Der Hautarzt 01/2008; 59(5):409-411. · 0.50 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Photodynamic therapy (PDT) relies on the interaction between a photosensitizer, the appropriate wavelength, and oxygen to cause cell death. First introduced about 100 years ago, PDT has continued to evolve in dermatology into a safe and effective treatment option for several dermatologic conditions. PDT is also used by pulmonologists, urologists, and ophthalmologists. This article focuses on the history of PDT, mechanism of action, photosensitizers and light sources used, therapeutic applications and expected dermatologic outcomes, as well as management of adverse events.
    Dermatologic clinics. 07/2014; 32(3):415-425.